Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023
On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023
On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023
Read more at prnewswire.com